Much-anticipated data from Arena Pharmaceuticals Inc.'s second Phase III study of lorcaserin didn't wow investors immediately, but the drug's impressive safety and tolerability profile left many analysts encouraged that it could find a place among stronger competitors in the growing obesity market. (BioWorld Today) Read More
